Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


PDL BioPharma, Inc. (PDLI) has entered into a settlement agreement with related entities of Defined Diagnostics, LLC, or Wellstat Parties, resolving litigation relating to loans made to Wellstat Diagnostics by PDL.


RTTNews | Aug 12, 2020 08:44AM EDT

08:43 Wednesday, August 12, 2020 (RTTNews.com) - PDL BioPharma, Inc. (PDLI) has entered into a settlement agreement with related entities of Defined Diagnostics, LLC, or Wellstat Parties, resolving litigation relating to loans made to Wellstat Diagnostics by PDL.

The loans totaling $44.1 million were made pursuant to a loan agreement between Wellstat Diagnostics and PDL dated August 2013, and the notes were carried on PDL's balance sheet for $51.39 million as of June 30, 2020. Wellstat Parties would pay an amount of $7.5 million upon the signing of the agreement and: either $5 million by February 10, 2021 and $55 million by July 26, 2021; or $67.5 million by July 26, 2021.

"We look forward to receiving the agreed payments, which should increase the net proceeds from our monetization strategy that we can ultimately distribute to our stockholders," said PDL's CEO Dominique Monnet.

Read the original article on RTTNews ( https://www.rttnews.com/3120842/pdl-biopharma-reaches-settlement-with-wellstat-parties-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC